Abstract
Aims and background: Malignant mesothelioma is associated with a median survival of 4 to 12 months. Data from the literature indicate that single modality treatment (surgery or intrapleural and/or systemic chemotherapy) does not significantly affect survival. Methods: We therefore evaluated a combined approach consisting of surgery (pleurectomy + diaphragmatic or pericardial resection), intrapleural chemotherapy with cisplatin (100 mg/m2) and cytarabine (1,000 mg/m2) tor 4 h immediately after pleurectomy, and systemic chemotherapy consisting of epirubicin (60 mg/m2) and mitomycin-C (10 mg/m2) day 1 every 4 weeks for 4 cycles. Results: Twenty patients were enrolled in the study and were evaluable. Thirteen cases had residual gross disease after pleurectomy and 7 patients only minimal disease. Median time to disease progression was 7.4 months, and median survival was 11.5 months (range, 2-25+). No treatment-related death have been observed. Side effects after intracavitary chemotherapy included renal toxicity, anaemia and pain. Myelosuppression and alopecia were recorded during systemic chemotherapy. Conclusions: The results of the study indicate that the schedule is feasible, with encouraging results in terms of survival for patients with minimal residual disease after surgery.
| Original language | English |
|---|---|
| Pages (from-to) | 53-56 |
| Number of pages | 4 |
| Journal | Tumori |
| Volume | 82 |
| Issue number | 1 |
| Publication status | Published - Jan 1996 |
Fingerprint
Keywords
- intracavitary chemotherapy
- mesothelioma
- surgery
- systemic chemotherapy
ASJC Scopus subject areas
- Cancer Research
Cite this
Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma. / Colleoni, Marco; Sartori, Francesco; Calabrò, Francesco; Nelli, Patrizia; Vicario, Giovanni; Sgarbossa, Gigliola; Gaion, Fernando; Bortolotti, Luigi; Toniolo, Lamberto; Manente, Paolo.
In: Tumori, Vol. 82, No. 1, 01.1996, p. 53-56.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma
AU - Colleoni, Marco
AU - Sartori, Francesco
AU - Calabrò, Francesco
AU - Nelli, Patrizia
AU - Vicario, Giovanni
AU - Sgarbossa, Gigliola
AU - Gaion, Fernando
AU - Bortolotti, Luigi
AU - Toniolo, Lamberto
AU - Manente, Paolo
PY - 1996/1
Y1 - 1996/1
N2 - Aims and background: Malignant mesothelioma is associated with a median survival of 4 to 12 months. Data from the literature indicate that single modality treatment (surgery or intrapleural and/or systemic chemotherapy) does not significantly affect survival. Methods: We therefore evaluated a combined approach consisting of surgery (pleurectomy + diaphragmatic or pericardial resection), intrapleural chemotherapy with cisplatin (100 mg/m2) and cytarabine (1,000 mg/m2) tor 4 h immediately after pleurectomy, and systemic chemotherapy consisting of epirubicin (60 mg/m2) and mitomycin-C (10 mg/m2) day 1 every 4 weeks for 4 cycles. Results: Twenty patients were enrolled in the study and were evaluable. Thirteen cases had residual gross disease after pleurectomy and 7 patients only minimal disease. Median time to disease progression was 7.4 months, and median survival was 11.5 months (range, 2-25+). No treatment-related death have been observed. Side effects after intracavitary chemotherapy included renal toxicity, anaemia and pain. Myelosuppression and alopecia were recorded during systemic chemotherapy. Conclusions: The results of the study indicate that the schedule is feasible, with encouraging results in terms of survival for patients with minimal residual disease after surgery.
AB - Aims and background: Malignant mesothelioma is associated with a median survival of 4 to 12 months. Data from the literature indicate that single modality treatment (surgery or intrapleural and/or systemic chemotherapy) does not significantly affect survival. Methods: We therefore evaluated a combined approach consisting of surgery (pleurectomy + diaphragmatic or pericardial resection), intrapleural chemotherapy with cisplatin (100 mg/m2) and cytarabine (1,000 mg/m2) tor 4 h immediately after pleurectomy, and systemic chemotherapy consisting of epirubicin (60 mg/m2) and mitomycin-C (10 mg/m2) day 1 every 4 weeks for 4 cycles. Results: Twenty patients were enrolled in the study and were evaluable. Thirteen cases had residual gross disease after pleurectomy and 7 patients only minimal disease. Median time to disease progression was 7.4 months, and median survival was 11.5 months (range, 2-25+). No treatment-related death have been observed. Side effects after intracavitary chemotherapy included renal toxicity, anaemia and pain. Myelosuppression and alopecia were recorded during systemic chemotherapy. Conclusions: The results of the study indicate that the schedule is feasible, with encouraging results in terms of survival for patients with minimal residual disease after surgery.
KW - intracavitary chemotherapy
KW - mesothelioma
KW - surgery
KW - systemic chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=15844374950&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=15844374950&partnerID=8YFLogxK
M3 - Article
C2 - 8623505
AN - SCOPUS:15844374950
VL - 82
SP - 53
EP - 56
JO - Tumori
JF - Tumori
SN - 0300-8916
IS - 1
ER -